Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
People diagnosed with cancer over a year ago and those who were not on treatment did not have a higher risk of hospitalization or death.
The largest peer-reviewed study of the Pfizer-BioNTech COVID vaccine in cancer patients finds no more, and no different, side effects.
Third booster dose may improve immune response in cancer patients without sufficient protection after second dose.
The booster is recommended for organ transplant recipients, people receiving cancer treatment and people with advanced or untreated HIV.
Experts call for heightened precautions and better, more intensive therapies for COVID-19 patients with weakened immune systems.
Some people with blood cancers, however, may not be as well protected.
The results challenge initial concerns that chemotherapy and other treatments were too dangerous to continue during the pandemic.
The coronavirus vaccines are safe and should be effective even for people with advanced cancer.
COVID-19 vaccines may be somewhat less effective for people on active treatment, but they should still get vaccinated. And it’s very safe.
The pandemic raises new concerns, but it may also lead to long-lasting improvements.
Recent studies suggest chemotherapy and immunotherapy are not linked to more severe COVID-19.
People with cancer, heart disease and diabetes are at increased risk for serious illness from COVID-19.
Data from a large COVID-19 and cancer registry also showed that hydroxychloroquine plus azithromycin is associated with higher mortality.
Cancer type, stage and treatment appear to affect the likelihood of poor outcomes.
Staying home for chemotherapy infusions and other treatments can save time and reduce anxiety surrounding contracting the virus.
Jenessa Schwartz refuses to put off joy even while battling Stage 4 colon cancer in the midst of a global pandemic.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.